EGFR-Non Small Cell Lung Cancer Market to Exhibit Rapid Growth Rate | Alpha Biopharma, Daiichi Sankyo Company, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, are expected to change the Market scenario by 2032, forecasts DelveInsight.

{Delhi, India} To strategically aid EGFR-Non Small Cell Lung Cancer companies developing drugs for EGFR-Non Small Cell Lung Cancer, DelveInsight launched a report titled as “Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insight, Epidemiology And Market Forecast - 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of EGFR-Non Small Cell Lung Cancer market.

Get a free sample of “Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (EGFR-NSCLC) Market Insights”: 

EGFR-Non Small Cell Lung Cancer Market Report’s Key Highlights:

• The Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer market size is expected to grow with a significant CAGR during the forecasted year 2023-2028
• The EGFR NSCLC market is projected to experience a consistent annual growth rate (CAGR) of 14.9% from 2019 to 2032. DelveInsight's projections suggest that the overall market size for EGFR-NSCLC is anticipated to expand across the seven major markets, thereby contributing significantly to the total NSCLC market size.
• Key EGFR-Non Small Cell Lung Cancer Companies: Avistone Pharmaceuticals, Black Diamond Therapeutics, Bayer, Bridge Therapeutics, RedCloud Bio, J Ints Bio, Cullinan Oncology, TYK Medicine, and others
• Key EGFR-Non Small Cell Lung Cancer Therapies: PLB1004, BDTX-1535, BAY2927088, BBT-176, H002, JIN-A02, CLN-081, TY-9591, and others
• The EGFR-Non Small Cell Lung Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR-Non Small Cell Lung Cancer pipeline products will significantly revolutionize the EGFR-Non Small Cell Lung Cancer market dynamics

EGFR-Non Small Cell Lung Cancer Country based Treatment Overview: 

The EGFR-Non Small Cell Lung Cancer treatment states the conventional and current medical therapies available in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market for the treatment of the condition. It also provides Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) treatment algorithms and guidelines in the United States, Europe, and Japan.

EGFR (Epidermal Growth Factor Receptor) is a protein found on the surface of cells and is involved in controlling cell growth. EGFR mutations are genetic alterations that can lead to the development of certain types of cancer, including non-small cell lung cancer (NSCLC).

To Know in detail about the EGFR-Non Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR-Non Small Cell Lung Cancer Market Forecast

EGFR-Non Small Cell Lung Cancer Epidemiology Insights: 

• The part discussing the epidemiology of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) offers information on past and present patient populations, as well as predictions for future trends in seven key countries.
• In 2020, there were 227,875 incident cases of lung cancer in the US, with around 85% of those patients being NSCLC patients (GLOBOCAN, n.d.).
• Of the five European nations, Germany had the greatest number of NSCLC cases. In addition, Japan will account for roughly 117,752 cases in 2020
• According to estimates, the United States has the largest incidence of EGFR-NSCLC, accounting for around 34% of all EGFR-mutated NSCLC cases in the 7MM (as of 2020). Furthermore, of the five European countries, Germany had the highest estimated incidence population of non-small cell lung cancer (29%), followed by the UK, France, Italy, and Spain
• The EGFR-Non Small Cell Lung Cancer epidemiology based on gender analyzed that 7 out of 10 patients had metastatic NSCLC (Stage IIIb and IV)

EGFR-Non Small Cell Lung Cancer Epidemiology Segmentation:

• Total Prevalence of EGFR-Non Small Cell Lung Cancer
• Prevalent Cases of EGFR-Non Small Cell Lung Cancer by severity
• Gender-specific Prevalence of EGFR-Non Small Cell Lung Cancer
• Diagnosed Cases of Episodic and Chronic EGFR-Non Small Cell Lung Cancer

Download the report to understand which factors are driving EGFR-Non Small Cell Lung Cancer epidemiology trends @ EGFR-Non Small Cell Lung Cancer Epidemiology Forecast

EGFR-Non Small Cell Lung Cancer Therapies and Key Companies

• PLB1004: Avistone Pharmaceuticals
• BDTX-1535: Black Diamond Therapeutics
• BAY2927088: Bayer
• BBT-176: Bridge Therapeutics
• H002: RedCloud Bio
• JIN-A02: J Ints Bio
• CLN-081: Cullinan Oncology
• TY-9591: TYK Medicine  

Emerging EGFR-Non Small Cell Lung Cancer drugs Uptake:

The section focusing on medications in the report on Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) contains a thorough examination of both the available drugs for EGFR-NSCLC and the developmental drugs in advanced stages (Phase III and Phase II) of the pipeline.

• In October 2023, Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the findings of the Phase 3 MARIPOSA-2 study, which demonstrated that the combination of chemotherapy and RYBREVANT® (amivantamab-vmjw), given with or without lazertinib, reduced the risk of death or disease progression by 56% and 56%, respectively (Hazard Ratio [HR]=0.44; 95 percent Confidence Interval [CI], 0.35–0.56; p value P<0.001 and HR=0.48; 95 percent CI, 0.36–0.64; P<0.001), when compared to chemotherapy alone in patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution after disease progression on or after osimertinib. The two RYBREVANT® regimens significantly increased the intracranial progression-free survival (PFS), duration of response (DOR), and objective response rate (ORR) in these patients when compared to chemotherapy alone, according to the results
• In June 2022, In order to determine the safety and effectiveness of TY-9591 versus Osimertinib in treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is known to be positive for the EGFR sensitizing mutation (EGFRm), treatment-naïve, and eligible for first-line treatment with an EGFR-TKI, TYK Medicines started a Phase III, double-blind, randomised study.
• Erlotinib (marketed as Tarceva by OSI Pharmaceuticals) works by blocking the autophosphorylation of EGFR tyrosine kinase within the intracellular domain. In November 2004, the United States Food and Drug Administration (FDA) granted regular approval for Erlotinib to treat patients diagnosed with locally advanced or metastatic NSCLC following the ineffectiveness of at least one prior chemotherapy regimen.
• Moreover, in the case of previously treated metastatic NSCLC with EGFR T790M mutation, the AURA3 trial assessed the effectiveness of Tagrisso. Tagrisso emerged as the preferred treatment option because of its demonstrated overall survival advantage in the FLAURA trial and its favorable safety profile.
• Multiple treatment choices exist for managing this condition within the seven primary markets. Conventionally, lung cancer is addressed through a combination of chemotherapy, targeted therapies, and immunotherapy, either separately or in conjunction. Additionally, surgical interventions and radiation therapy are commonly selected alongside pharmaceutical treatments as viable options.

Discover more about therapies set to grab major EGFR-Non Small Cell Lung Cancer market share @ EGFR-Non Small Cell Lung Cancer Treatment Market

EGFR-Non Small Cell Lung Cancer Market Forecast: 

Currently, Tagrisso (osimertinib) holds a significant share in the EGFR-positive NSCLC market. While other treatments such as platinum-based chemotherapy, first and second-generation TKIs, and Vizimpro (dacomitinib) also contribute to the market, Tagrisso stands out. Future growth in the therapeutic market is anticipated, particularly driven by medications targeting EGFR exon 20 insertion mutations like TAK-788 and similar agents. Nonetheless, Tagrisso is foreseen to maintain its position as the standard of care and continue dominating the market in the future.

The EGFR-Non Small Cell Lung Cancer market drivers include- Increasing Use of Biomarker Testing Increasing Incidence of NSCLC, Increase in the Mutation Specific Trials Activity and Approval, Rich Pipeline and label expansion of approved therapies.

Scope of the EGFR-Non Small Cell Lung Cancer Market Report: 

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Key Companies: Alpha Biopharma, Daiichi Sankyo Company,Suzhou Puhe Pharmaceutical Technology, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, Cullinan Oncology, Betta Pharmaceuticals, EpimAb Biotherapeutics, Genor Biopharma, G1 Therapeutics, J Ints Bio, and others.

To know more about EGFR-Non Small Cell Lung Cancer companies working in the treatment market, visit @ EGFR-Non Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the EGFR-Non Small Cell Lung Cancer market landscape.

• Gain Competitive Edge in Indication Market: Understand the current landscape of the EGFR-Non Small Cell Lung Cancer market, including the competitive environment, key companies developing drugs for EGFR-Non Small Cell Lung Cancer, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the EGFR-Non Small Cell Lung Cancer market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with EGFR-Non Small Cell Lung Cancer. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success: Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the EGFR-Non Small Cell Lung Cancer market with clarity and purpose. 

Related Reports:

EGFR-Non Small Cell Lung Cancer Pipeline  

“EGFR-Non Small Cell Lung Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the EGFR-Non Small Cell Lung Cancer market. A detailed picture of the EGFR-Non Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and EGFR-Non Small Cell Lung Cancer treatment guidelines. 

Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European biosimilar landscape. Download Pharma Go-to-Market Case Study!

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/consulting